• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Labcorp and Epic Expand Collaboration to Advance Diagnostic Integration across Hospitals and Health Systems

    5/12/26 7:00:00 AM ET
    $LH
    Medical Specialities
    Health Care
    Get the next $LH alert in real time by email
    • Labcorp's full test menu will be available through Epic's Aura platform
    • Integration builds on the successful deployment of Invitae genetic testing and accelerates access to the latest genetic and specialty diagnostics through Aura
    • Collaboration will help reduce IT complexity, streamline lab ordering and improve access to diagnostic innovation for hospitals and health systems using Epic nationwide

    BURLINGTON, N.C., May 12, 2026 /PRNewswire/ -- Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, today announced an expanded collaboration with Epic, the nation's leading electronic health record (EHR) supporting hospitals and health systems. Through the collaboration, Labcorp's full test menu will be available through Aura, Epic's unified platform for ordering and receiving lab results. The integration will drive meaningful operational efficiencies, streamline lab ordering for clinicians and care teams, and improve access to diagnostic innovation for hospitals and health systems using Epic nationwide.

    Labcorp Logo (PRNewsfoto/Labcorp)

    Reducing Complexity and Expanding Access to Testing and Diagnostic Innovation

    Health systems often face lengthy, complex and time-consuming IT projects to integrate with laboratory partners. By leveraging Epic's Aura, the expansion will reduce the time, cost and ongoing maintenance typically required for lab interfaces. Building on the availability of Invitae genetic tests through Aura, part of Labcorp's diagnostic portfolio, health systems will be able to access Labcorp's full test menu and new tests as they are introduced directly within their existing Epic workflows.

    "This expanded collaboration reflects how Labcorp is investing to meet the evolving needs of hospitals and health systems," said Bryan Vaughn, Executive Vice President and President of Diagnostics at Labcorp. "By simplifying lab integrations and delivering our full test menu directly within Epic workflows, we are expanding access and building a strong foundation for continued innovation."

    Benefits for Clinicians and Health Systems

    The expanded integration will deliver meaningful benefits including:

    • Simplified onboarding and maintenance – Aura's connectivity and content‑management capabilities reduce the effort required to onboard and maintain Labcorp's test menu, reducing integration complexity for hospitals and health systems.
    • Seamless access within Epic workflows – Clinicians will be able to order Labcorp tests and receive discrete results directly within their Epic workflow, improving efficiency and reducing reliance on manual processes or workarounds.
    • Broader access to Labcorp's full and evolving test menu, including new and advanced diagnostics.

    "Expanding Labcorp's use of Aura to include its full test menu makes it easy for clinicians to order the right test the first time, right from their workflow, so patients get accurate answers faster," said Sumit Rana, President of Epic.

    To learn more about Labcorp's ongoing collaboration with Epic and future plans to advance diagnostic integration for hospitals and health systems, visit https://www.labcorp.com/organizations/epic. 

    About Labcorp

    Labcorp (NYSE:LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company's nearly 71,000 employees serve clients in approximately 100 countries, provided support for more than 85% of the new drugs and therapeutic products approved by the FDA in 2025 and performed more than 750 million tests for patients around the world. Learn more at www.labcorp.com.

    Cautionary Statement Regarding Forward-Looking Statements

    This press release contains forward-looking statements, including, but not limited to, statements with respect to the expected utility and benefits of integrating Labcorp's full test menu into the Epic Aura platform.

    Each of the forward-looking statements is subject to change based on various important factors, many of which are beyond the company's control. These factors, in some cases, have affected and in the future (together with other factors) could affect the company's ability to implement the company's business strategy, and actual results could differ materially from those suggested by these forward-looking statements. As a result, readers are cautioned not to place undue reliance on any of the forward-looking statements.

    The company has no obligation to provide any updates to these forward-looking statements even if its expectations change. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. Further information on potential factors, risks and uncertainties that could affect operating and financial results is included in the company's most recent Annual Report on Form 10-K under the heading RISK FACTORS and in the company's other filings with the SEC. The information in this press release should be read in conjunction with a review of the company's filings with the SEC including the information in the company's most recent Annual Report on Form 10-K under the heading "MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS."

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/labcorp-and-epic-expand-collaboration-to-advance-diagnostic-integration-across-hospitals-and-health-systems-302768704.html

    SOURCE Labcorp

    Get the next $LH alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LH

    DatePrice TargetRatingAnalyst
    7/10/2025$260.00Buy → Hold
    HSBC Securities
    4/2/2025$276.00Buy
    Redburn Atlantic
    3/4/2025$250.00 → $300.00Neutral → Buy
    Citigroup
    1/7/2025$260.00 → $265.00In-line → Outperform
    Evercore ISI
    12/10/2024$265.00 → $275.00Buy
    Jefferies
    10/30/2024Hold → Buy
    HSBC Securities
    10/1/2024$235.00Neutral
    Piper Sandler
    3/25/2024$250.00Hold → Buy
    Argus
    More analyst ratings

    $LH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Labcorp to Announce Second Quarter 2026 Financial Results on July 30, 2026

    BURLINGTON, N.C., June 30, 2026 /PRNewswire/ -- Labcorp Holdings Inc. (NYSE:LH), a global leader of innovative and comprehensive laboratory services, will release its financial results for the second quarter of 2026 before the market opens on Thursday, July 30, 2026. The company will host a webcast beginning at 9:00 a.m. ET that day to discuss the results. The earnings press release and accompanying financial information will be posted on the "News & Events" section of the Labcorp Investor Relations website at https://ir.labcorp.com. A link to the earnings webcast will also be available on the investor relations website.

    6/30/26 4:15:00 PM ET
    $LH
    Medical Specialities
    Health Care

    Labcorp Announces Nationwide Availability of ColoSense®, the First FDA-Approved RNA-Based At-Home Colorectal Cancer Screening Test

    First FDA-approved, at-home screening test that uses RNA technology to detect biomarkers associated with colorectal cancer and advanced adenomasDesigned to reduce common barriers to at-home screening with a cleaner, simplified collection experience that minimizes sample handling Meets screening guidelines from the American Cancer Society (ACS) and National Comprehensive Cancer Network (NCCN)BURLINGTON, N.C. and ST. LOUIS, June 22, 2026 /PRNewswire/ -- Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, today announced the nationwide availability of ColoSense®, the only RNA-based at-home test for colorectal cancer (CRC) screening approved by the U.S. Food a

    6/22/26 7:00:00 AM ET
    $LH
    Medical Specialities
    Health Care

    Labcorp Supports Multi-Institution Trial to Expand Genetic Testing in Colorectal Cancer

    Collaborative trial with Alliance for Clinical Trials in Oncology will evaluate new approaches to increase germline genetic testing among at-risk family membersResearch will also assess the clinical impact of broader genetic testing in colorectal cancer careBURLINGTON, N.C., May 29, 2026 /PRNewswire/ -- Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, today announced a collaboration with the Alliance for Clinical Trials in Oncology to advance a national, multicenter clinical trial for patients newly diagnosed with colorectal cancer (CRC). The trial will evaluate approaches to increase germline genetic testing among at-risk family members, as well as the

    5/29/26 7:00:00 AM ET
    $LH
    Medical Specialities
    Health Care

    $LH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Labcorp Holdings Inc. downgraded by HSBC Securities with a new price target

    HSBC Securities downgraded Labcorp Holdings Inc. from Buy to Hold and set a new price target of $260.00

    7/10/25 9:03:30 AM ET
    $LH
    Medical Specialities
    Health Care

    Redburn Atlantic initiated coverage on Labcorp Holdings Inc. with a new price target

    Redburn Atlantic initiated coverage of Labcorp Holdings Inc. with a rating of Buy and set a new price target of $276.00

    4/2/25 8:50:29 AM ET
    $LH
    Medical Specialities
    Health Care

    Labcorp Holdings Inc. upgraded by Citigroup with a new price target

    Citigroup upgraded Labcorp Holdings Inc. from Neutral to Buy and set a new price target of $300.00 from $250.00 previously

    3/4/25 7:36:42 AM ET
    $LH
    Medical Specialities
    Health Care

    $LH
    SEC Filings

    View All

    $LH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Labcorp Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - LABCORP HOLDINGS INC. (0000920148) (Filer)

    7/10/26 7:31:41 AM ET
    $LH
    Medical Specialities
    Health Care

    Labcorp Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - LABCORP HOLDINGS INC. (0000920148) (Filer)

    6/30/26 4:20:07 PM ET
    $LH
    Medical Specialities
    Health Care

    Labcorp Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - LABCORP HOLDINGS INC. (0000920148) (Filer)

    5/27/26 8:04:15 AM ET
    $LH
    Medical Specialities
    Health Care

    EVP, Chief Legal Officer Kyle Kathryn W converted options into 256 shares, covered exercise/tax liability with 73 shares and sold $26,329 worth of shares (92 units at $286.19) as part of a pre-agreed trading plan, increasing direct ownership by 2% to 3,904 units (SEC Form 4) (for withholding tax)

    4 - LABCORP HOLDINGS INC. (0000920148) (Issuer)

    7/6/26 9:37:55 AM ET
    $LH
    Medical Specialities
    Health Care

    EVP and President, Diagnostics Vaughn Bryan T covered exercise/tax liability with 93 shares, sold $66,968 worth of shares (234 units at $286.19) as part of a pre-agreed trading plan and converted options into 327 shares (SEC Form 4) (for withholding tax)

    4 - LABCORP HOLDINGS INC. (0000920148) (Issuer)

    7/6/26 9:36:47 AM ET
    $LH
    Medical Specialities
    Health Care

    EVP, Chief Legal Officer Kyle Kathryn W sold $201,084 worth of shares (762 units at $263.89) as part of a pre-agreed trading plan, decreasing direct ownership by 17% to 3,813 units (SEC Form 4)

    4 - LABCORP HOLDINGS INC. (0000920148) (Issuer)

    6/10/26 9:01:40 AM ET
    $LH
    Medical Specialities
    Health Care

    $LH
    Leadership Updates

    Live Leadership Updates

    View All

    Middleby Appoints Glenn Eisenberg To Board of Directors

    The Middleby Corporation (NASDAQ:MIDD), a global leader in the foodservice industry, today announced the appointment of Glenn Eisenberg to its Board of Directors, effective March 1. With the addition of Mr. Eisenberg, the Middleby Board expands to twelve members. "We are pleased to welcome Glenn Eisenberg to the Middleby Board. His deep experience will be an immediate asset as we execute our strategic transformation," said Tim FitzGerald, Middleby CEO. "Glenn has a proven 20-year track record of success as a public company CFO and senior operating executive across complex global manufacturing businesses. His expertise in financial discipline, industrial manufacturing, capital allocation,

    3/6/26 7:00:00 AM ET
    $LH
    $LMRI
    $MIDD
    Medical Specialities
    Health Care
    Industrial Machinery/Components
    Industrials

    Labcorp Appoints John H. Sampson, M.D., Ph.D., to Board of Directors

    BURLINGTON, N.C., Feb. 9, 2026 /PRNewswire/ -- Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, today announced the appointment of John H. Sampson, M.D., Ph.D., MHSc, MBA, to its Board of Directors, effective February 9, 2026. Dr. Sampson serves as vice chancellor for health affairs and dean of the University of Colorado Anschutz School of Medicine at the CU Anschutz medical campus. As a nationally recognized neurosurgeon, physician-scientist and academic leader, Dr. Sampson brings extensive experience spanning clinical care, biomedical r

    2/9/26 8:30:00 AM ET
    $LH
    Medical Specialities
    Health Care

    Labcorp Appoints Victor Bulto to Board of Directors

    Bulto, President, U.S. of Novartis, brings global healthcare leadership and growth track record to support Labcorp's long-term strategy BURLINGTON, N.C., Nov. 24, 2025 /PRNewswire/ -- Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, today announced the appointment of Victor Bulto, a seasoned pharmaceutical executive and member of Novartis' executive leadership team, to its Board of Directors, effective December 1, 2025. Bulto is an accomplished global executive with 25 years of experience in healthcare, and a proven track record of leadin

    11/24/25 8:30:00 AM ET
    $LH
    Medical Specialities
    Health Care

    $LH
    Financials

    Live finance-specific insights

    View All

    Labcorp Announces 2026 First Quarter Results; Raises Full Year 2026 Guidance

    Results from Operations for first quarter 2026 versus first quarter 2025:Revenue: $3.54 billion vs. $3.35 billion, up 5.8%Diluted EPS: $3.35 vs. $2.52, up 32.8%Adjusted EPS: $4.25 vs. $3.84, up 10.6%Raised Full-Year Enterprise Revenue and Adjusted EPS guidance:Revenue guidance of 5.0% to 6.1%; up 20 basis points at the midpointAdjusted EPS range of $17.70 to $18.35; up 13 cents at the midpointAdvanced leadership in specialty and companion diagnostics and expanded strategic health systems collaborationsCollaborated with Optum.ai to enhance patient and provider experienceBURLINGTON, N.C., April 30, 2026 /PRNewswire/ -- Labcorp Holdings Inc (NYSE:LH), a global leader of innovative and comprehen

    4/30/26 6:50:00 AM ET
    $LH
    Medical Specialities
    Health Care

    Labcorp Declares Quarterly Dividend

    BURLINGTON, N.C., April 9, 2026 /PRNewswire/ -- Labcorp Holdings Inc. (NYSE:LH), a global leader of innovative and comprehensive laboratory services, announced today that its Board of Directors has declared a cash dividend of $0.72 per share of common stock. The dividend will be payable on June 11, 2026, to stockholders of record as of the close of business on May 29, 2026. About LabcorpLabcorp (NYSE:LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident

    4/9/26 6:50:00 AM ET
    $LH
    Medical Specialities
    Health Care

    Labcorp Announces 2025 Fourth Quarter and Full Year Results

    Company Provides 2026 GuidanceFinancial results from Operations versus 2024:Revenue: Q4 of $3.52 billion vs $3.33 billion; Full year of $13.95 billion vs $13.01 billionDiluted EPS: Q4 of $1.98 vs $1.70; Full year of $10.46 vs $8.84Adjusted EPS: Q4 of $4.07 vs $3.45; Full year of $16.44 vs $14.57Free Cash Flow: Q4 of $490.3 million vs. $665.1 million; Full year of $1.21 billion vs $1.10 billionProvided Full-Year 2026 Enterprise Revenue, Adjusted EPS and Free Cash Flow guidance:Revenue of $14.61 billion to $14.79 billion; midpoint growth of 5.4%Adjusted EPS of $17.55 to $18.25; midpoint growth of 8.9%Free Cash Flow of $1.24 billion to $1.36 billion; midpoint growth of 7.8%Expanded partnerships

    2/17/26 6:50:00 AM ET
    $LH
    Medical Specialities
    Health Care

    $LH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Laboratory Corporation of America Holdings (Amendment)

    SC 13G/A - LABORATORY CORP OF AMERICA HOLDINGS (0000920148) (Subject)

    2/13/24 5:08:06 PM ET
    $LH
    Medical Specialities
    Health Care

    SEC Form SC 13D/A filed by Laboratory Corporation of America Holdings (Amendment)

    SC 13D/A - LABORATORY CORP OF AMERICA HOLDINGS (0000920148) (Filed by)

    7/24/23 4:20:26 PM ET
    $LH
    Medical Specialities
    Health Care

    SEC Form SC 13G/A filed

    SC 13G/A - LABORATORY CORP OF AMERICA HOLDINGS (0000920148) (Subject)

    2/10/21 11:14:27 AM ET
    $LH
    Medical Specialities
    Health Care